The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery

• Status: Withdrawn
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients over 60, who came to the orthopedic department for proximal femur fracture surgery

• Sound judgment

Exclusion Criteria:

• Known hypersensitivity to Tranexamic Acid or component solution provided

• Subarachnoid hemorrhage

• Acquired color blindness

• Myocardial infarction in 12 months before admission

• Unstable angina

• Known clotting disorders (Thromboembolic disease in the past, elongated PT and PTT, hypercoagulability),

• Kidney or liver failure

• Another situation prostate resection , pathologic fractures according to anamnesis or by imaging

• Oncology patients

• Patients on anticoagulation

• Patients undergoing vascular intervention ( coronary or peripheral ), which was inserted Supporter requires a Dual antiplatelet therapy